# MB-CART20.1 Lymphoma

> **NCT03664635** · PHASE1,PHASE2 · COMPLETED · sponsor: **Miltenyi Biomedicine GmbH** · enrollment: 10 (actual)

## Conditions studied

- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- B-cell Lymphoma Refractory
- B-cell Lymphoma Recurrent

## Interventions

- **BIOLOGICAL:** MB-CART20.1

## Key facts

- **NCT ID:** NCT03664635
- **Lead sponsor:** Miltenyi Biomedicine GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-25
- **Primary completion:** 2024-09-17
- **Final completion:** 2024-09-17
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03664635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03664635, "MB-CART20.1 Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03664635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*